Trial Profile
Clinical Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Urinary Albumin to Creatinine Ratio in Patients With Overt Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Aug 2016 Status changed from recruiting to discontinued.
- 05 Mar 2014 New trial record